| Trial ID: | L0837 |
| Source ID: | NCT02974374
|
| Associated Drug: |
PF-06835919
|
| Title: |
A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess Safety, Tolerability And Pharmacokinetics Of Single, Escalating, Oral Doses Of Pf-06835919 In Healthy Adult Subjects
|
| Acronym: |
--
|
| Status: |
Not recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-alcoholic Fatty Liver Disease;Non-alcoholic Fatty Liver Disease;Non-alcoholic Fatty Liver Disease;Non-alcoholic Fatty Liver Disease
|
| Interventions: |
Drug: PF-06835919;Other: Placebo;Drug: PF-06835919;Other: Placebo;Drug: PF-06835919;Other: Placebo;Drug: PF-06835919;Other: Placebo
|
| Outcome Measures: |
Number of Subjects experiencing an Adverse Event;Number of Subjects experiencing an Adverse Event;Number of Subjects experiencing an Adverse Event;Number of Subjects experiencing an Adverse EventMaximum Observed Plasma Concentration (Cmax) for PF-06835919;Time to Reach Maximum Observed Concentration for PF-06835919;Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06835919;Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0- infinity)] for PF-06835919;Plasma Decay Half-Life (t1/2) for PF-06835919 (as permitted);Apparent Total Body Clearance (CL/F) for PF-06835919 (as permitted);Apparent Volume of Distribution (Vz/F) for PF-06835919 (as permitted)
|
| Sponsor/Collaborators: |
Pfizer
|
| Gender: |
All
|
| Age: |
18 Years55 Years
|
| Phases: |
Phase 1
|
| Enrollment: |
16
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).
|
| Start Date: |
11/10/2016
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
8 January 2018
|
| Locations: |
United States;United States;United States;United States
|
| URL: |
https://clinicaltrials.gov/show/NCT02974374
|
